



April 14, 2023

To,  
Listing/ Compliance Department  
**BSE LTD.**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

**SCRIP CODE: 543748**

Dear Sir/Madam,

To,  
Listing/ Compliance Department  
**National Stock Exchange of  
India Limited**  
“Exchange Plaza”, Plot No. C/1,  
G Block, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
**SYMBOL: AARTIPHARM**

**Sub: Certificate pursuant to Regulation 40(9) of the  
SEBI (LODR) Regulations, 2015**

---

Please find enclosed herewith the Certificate as per Regulation 40(9) of the SEBI (LODR) Regulations, 2015, for the year ended March 31, 2023, received from Mehta & Mehta, Company Secretaries in Practice.

Please take the same on your records.

Thanking you,

Yours faithfully,  
For **AARTI PHARMALABS LIMITED**  
(Formerly known as Aarti Organics Limited)

NIKHIL NATU  
**COMPANY SECRETARY**  
ICSI M. NO. A27738

Encl. a/a.

**AARTI PHARMALABS LIMITED**

**www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com**

**Admin Office :** 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234  
**Regd. Office :** Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655

# Mehta & Mehta

## COMPANY SECRETARIES

201-206, SHIV SMRITI, 2ND FLOOR, 49/A, DR. ANNIE BESANT ROAD, ABOVE CORPORATION BANK, WORLI, MUMBAI-400 018  
TEL : +91-22-6611 9696. • E-mail: dipti@mehta-mehta.com. • Visit us : www.mehta-mehta.com

**AUTHORISED AGENTS FOR TRADEMARK, COPYRIGHT AND PATENT**

**Date : April 14, 2023**


To,  
The Board of Directors  
**Aarti Pharmalabs Limited**  
**(Formerly known as Aarti Organics Limited)**  
Plot No. 22/C/1 & 22/C/2, 1<sup>st</sup> Phase,  
G.I.D.C. Vapi, Valsad GJ 396195 India

Dear Sir/ Madam,

**Sub: - Certificate under Regulation 40 (9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

On the basis of record and other documents received on E-mail from **Aarti Pharmalabs Limited ("the Company")** maintained by **Link Intime India Private Limited (Registrar & Share Transfer Agent)** pertaining to transfer, sub-division, consolidation, renewal, exchange etc. of equity shares of the Company for the period from **1<sup>st</sup> April, 2022 to 31<sup>st</sup> March, 2023** for the purpose of issuing a Certificate as per **Regulation 40 (9)** of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 entered into by the Company with **BSE Limited** and **National Stock Exchange of India Limited**, we hereby certify that the Company has **not received** any request for transfer, sub-division, consolidation, renewal, exchange etc. for **the year ended 31<sup>st</sup> March, 2023**.

**FOR MEHTA & MEHTA**  
**Unique Code No.: P1996MH007500**  
**Company Secretaries,**



**Partner**  
**CS Ashwini Inamdar**  
**UDIN: F009409E000093251**

